Participants were given an 8 mg dose of BPL-003, followed by a 12 mg dose 2 weeks later. Furthermore, the second dose of BPL-003 increased the proportion of participants meeting response and remission criteria for depression. They suggest that a second dose of BPL-003 not only maintains, but potentially deepens, antidepressant effects while remaining well-tolerated. References1. atai Life Sciences and Beckley Psytech report positive phase 2a data demonstrating improved outcomes with a two-dose induction regimen of BPL-003 in patients with treatment-resistant depression. Kuntz L. Positive results from the phase 2b study of BPL-003 in patients with treatment-resistant depression.